Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE